NASDAQ: IMNMImmunome Inc Stock
$14.26-0.01 (-0.07%)
Updated Apr 25, 2024
IMNM Price
$14.26
Fair Value Price
$1.65
Market Cap
$851.24M
52 Week Low
$4.44
52 Week High
$30.96
P/E
-2.65x
P/B
7.1x
P/S
15.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.02M
Earnings
-$106.81M
Gross Margin
100%
Operating Margin
-761.92%
Profit Margin
-761.9%
Debt to Equity
0.24
Operating Cash Flow
-$8M
Beta
1.36
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IMNM Overview
Immunome Incorporated is a biopharmaceutical company developing antibody therapeutics for oncology and infectious disease. Its pipeline includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoints capable of promoting evasion of the immune system, and IMM-BCP-01, an antibody cocktail for the treatment of SARS-CoV-2 infections and COVID-19. Immunome was incorporated in 2006 and is headquartered in Exton, PA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMNM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMNM ($14.26) is overvalued by 763.33% relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMNM ($14.26) is not significantly undervalued (763.33%) relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMNM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMNM due diligence checks available for Premium users.
Be the first to know about important IMNM news, forecast changes, insider trades & much more!
IMNM News
Valuation
IMNM fair value
Fair Value of IMNM stock based on Discounted Cash Flow (DCF)
Price
$14.26
Fair Value
$1.65
Overvalued by
763.33%
IMNM ($14.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMNM ($14.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMNM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMNM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.65x
Industry
15.41x
Market
40.97x
IMNM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.1x
Industry
5.8x
IMNM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMNM's financial health
Profit margin
Revenue
$3.8M
Net Income
-$92.6M
Profit Margin
-2,421.2%
IMNM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMNM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$148.5M
Liabilities
$28.7M
Debt to equity
0.24
IMNM's short-term assets ($144.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMNM's short-term assets ($144.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMNM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMNM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.5M
Investing
-$30.0M
Financing
$55.5M
IMNM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMNM vs Biotech Stocks
Immunome Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.